# Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

> **NCT02446912** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 460 (actual)

## Conditions studied

- Active Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Anifrolumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02446912
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-09
- **Primary completion:** 2018-07-17
- **Final completion:** 2018-07-17
- **Target enrollment:** 460 (ACTUAL)
- **Last updated:** 2023-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446912, "Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02446912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*